• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

癌/睾丸抗原NY-SAR-35对癌细胞增殖、迁移和侵袭的影响。

Effect of cancer/testis antigen NY-SAR-35 on the proliferation, migration and invasion of cancer cells.

作者信息

Song Myung-Ha, Kim Ye-Rin, Bae Jae-Ho, Lee Chang-Hun, Lee Sang-Yull

机构信息

Department of Biochemistry, School of Medicine, Pusan National University, Yangsan, Gyeongsangnam-do 626-870, Republic of Korea.

Department of Pathology, School of Medicine, Pusan National University, Yangsan, Gyeongsangnam-do 626-870, Republic of Korea.

出版信息

Oncol Lett. 2017 Feb;13(2):784-790. doi: 10.3892/ol.2016.5498. Epub 2016 Dec 14.

DOI:10.3892/ol.2016.5498
PMID:28356959
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5351105/
Abstract

NY-SAR-35 is a cancer/testis (CT) antigen that was identified by serological analysis of recombinant complementary DNA expression libraries. The gene encoding NY-SAR-35 is located on the × chromosome and is aberrantly expressed in a number of cancer types and germ cells, such as those in the testes, but not in normal tissue. It has been reported that treatment with a demethylating agent induced the expression of NY-SAR-35 in several types of cancer cells. However, the function of NY-SAR-35 in cancer remains undetermined. In present study, the role of NY-SAR-35 in human lung adenocarcinoma (SK-LC-14) and hepatocellular carcinoma (SNU-449) cells was investigated following stable transfection of the NY-SAR-35 gene. NY-SAR-35 was observed to be expressed in the cytoplasm of the cells. In addition, the bromodeoxyuridine incorporation assay and immunofluorescence staining for proliferating cell nuclear antigen and Ki-67 demonstrated that proliferation was increased in cells transfected with NY-SAR-35. In addition, the trypan blue exclusion assay indicated that NY-SAR-35 increased cancer cell viability. Furthermore, NY-SAR-35 increased the migration and invasion of the cells. These results indicate that NY-SAR-35 increases cancer cell viability, proliferation, migration and invasion.

摘要

NY-SAR-35是一种癌胚（CT）抗原，通过重组互补DNA表达文库的血清学分析得以鉴定。编码NY-SAR-35的基因位于X染色体上，在多种癌症类型和生殖细胞（如睾丸中的生殖细胞）中异常表达，但在正常组织中不表达。据报道，用去甲基化剂处理可诱导NY-SAR-35在几种癌细胞类型中表达。然而，NY-SAR-35在癌症中的功能仍未确定。在本研究中，在稳定转染NY-SAR-35基因后，研究了NY-SAR-35在人肺腺癌（SK-LC-14）和肝癌（SNU-449）细胞中的作用。观察到NY-SAR-35在细胞的细胞质中表达。此外，溴脱氧尿苷掺入试验以及针对增殖细胞核抗原和Ki-67的免疫荧光染色表明，转染NY-SAR-35的细胞增殖增加。此外，台盼蓝排斥试验表明NY-SAR-35提高了癌细胞的活力。此外，NY-SAR-35增加了细胞的迁移和侵袭能力。这些结果表明，NY-SAR-35可提高癌细胞的活力、增殖、迁移和侵袭能力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9dce/5351105/a8293dca6b39/ol-13-02-0784-g03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9dce/5351105/71abe3a21476/ol-13-02-0784-g00.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9dce/5351105/f98d4022740a/ol-13-02-0784-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9dce/5351105/77041074e2f9/ol-13-02-0784-g02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9dce/5351105/a8293dca6b39/ol-13-02-0784-g03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9dce/5351105/71abe3a21476/ol-13-02-0784-g00.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9dce/5351105/f98d4022740a/ol-13-02-0784-g01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9dce/5351105/77041074e2f9/ol-13-02-0784-g02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9dce/5351105/a8293dca6b39/ol-13-02-0784-g03.jpg

相似文献

1
Effect of cancer/testis antigen NY-SAR-35 on the proliferation, migration and invasion of cancer cells.癌/睾丸抗原NY-SAR-35对癌细胞增殖、迁移和侵袭的影响。
Oncol Lett. 2017 Feb;13(2):784-790. doi: 10.3892/ol.2016.5498. Epub 2016 Dec 14.
2
Cancer/testis antigen NY-SAR-35 enhances cell proliferation, migration, and invasion.癌/睾丸抗原NY-SAR-35可增强细胞增殖、迁移和侵袭能力。
Int J Oncol. 2016 Feb;48(2):569-76. doi: 10.3892/ijo.2015.3264. Epub 2015 Nov 24.
3
A cancer/testis antigen, NY-SAR-35, induces EpCAM, CD44, and CD133, and activates ERK in HEK293 cells.一种癌/睾丸抗原NY-SAR-35可诱导人胚肾293细胞（HEK293细胞）中上皮细胞黏附分子（EpCAM）、CD44和CD133的表达，并激活细胞外信号调节激酶（ERK）。
Biochem Biophys Res Commun. 2017 Mar 4;484(2):298-303. doi: 10.1016/j.bbrc.2017.01.105. Epub 2017 Jan 23.
4
Expression of the human cancer/testis antigen NY-SAR-35 is activated by CpG island hypomethylation.人类肿瘤/睾丸抗原 NY-SAR-35 的表达受 CpG 岛低甲基化激活。
Biotechnol Lett. 2011 Jun;33(6):1085-91. doi: 10.1007/s10529-011-0559-y. Epub 2011 Feb 12.
5
Immunomic analysis of human sarcoma.人类肉瘤的免疫组学分析
Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2651-6. doi: 10.1073/pnas.0437972100. Epub 2003 Feb 24.
6
Identification of a tissue-specific putative transcription factor in breast tissue by serological screening of a breast cancer library.通过对乳腺癌文库进行血清学筛选鉴定乳腺组织中的一种组织特异性假定转录因子。
Cancer Res. 2001 Mar 1;61(5):2055-61.
7
MAGE-A1, GAGE and NY-ESO-1 cancer/testis antigen expression during human gonadal development.人性腺发育过程中MAGE-A1、GAGE和NY-ESO-1癌胚抗原的表达
Hum Reprod. 2007 Apr;22(4):953-60. doi: 10.1093/humrep/del494. Epub 2007 Jan 5.
8
Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues.人正常组织和恶性组织中NY-ESO-1抗原表达的免疫组织化学分析。
Int J Cancer. 2001 Jun 15;92(6):856-60. doi: 10.1002/ijc.1282.
9
Reciprocal binding of CTCF and BORIS to the NY-ESO-1 promoter coincides with derepression of this cancer-testis gene in lung cancer cells.CTCF和BORIS与NY-ESO-1启动子的相互结合与肺癌细胞中该癌胚基因的去抑制同时发生。
Cancer Res. 2005 Sep 1;65(17):7763-74. doi: 10.1158/0008-5472.CAN-05-0823.
10
Identification of tumor-restricted antigens NY-BR-1, SCP-1, and a new cancer/testis-like antigen NW-BR-3 by serological screening of a testicular library with breast cancer serum.通过用乳腺癌血清对睾丸文库进行血清学筛选来鉴定肿瘤限制性抗原NY-BR-1、SCP-1以及一种新的癌/睾丸样抗原NW-BR-3。
Cancer Immun. 2002 Jun 28;2:5.

引用本文的文献

1
FMR1NB Involved in Glioma Tumorigenesis Is a Promising Target for Prognosis and Therapy.FMR1NB 参与脑肿瘤发生，是预后和治疗的有希望的靶点。
Curr Med Sci. 2022 Aug;42(4):803-816. doi: 10.1007/s11596-022-2586-4. Epub 2022 Jul 11.
2
Cancer/Testis Antigens as Biomarker and Target for the Diagnosis, Prognosis, and Therapy of Lung Cancer.癌胚抗原作为肺癌诊断、预后和治疗的生物标志物及靶点
Front Oncol. 2022 Apr 27;12:864159. doi: 10.3389/fonc.2022.864159. eCollection 2022.

本文引用的文献

1
Cancer/testis antigen NY-SAR-35 enhances cell proliferation, migration, and invasion.癌/睾丸抗原NY-SAR-35可增强细胞增殖、迁移和侵袭能力。
Int J Oncol. 2016 Feb;48(2):569-76. doi: 10.3892/ijo.2015.3264. Epub 2015 Nov 24.
2
Status of hepatocellular carcinoma in South Korea.韩国肝细胞癌的现状。
Chin Clin Oncol. 2013 Dec;2(4):39. doi: 10.3978/j.issn.2304-3865.2013.11.08.
3
Cause and consequence of cancer/testis antigen activation in cancer.癌症中癌/睾丸抗原激活的原因和后果。
Annu Rev Pharmacol Toxicol. 2014;54:251-72. doi: 10.1146/annurev-pharmtox-011112-140326. Epub 2013 Oct 11.
4
The novelty of human cancer/testis antigen encoding genes in evolution.人类癌症/睾丸抗原编码基因在进化中的新颖性。
Int J Genomics. 2013;2013:105108. doi: 10.1155/2013/105108. Epub 2013 Apr 18.
5
Cancer statistics in Korea: incidence, mortality, survival and prevalence in 2010.韩国癌症统计数据：2010 年的发病率、死亡率、生存率和流行率。
Cancer Res Treat. 2013 Mar;45(1):1-14. doi: 10.4143/crt.2013.45.1.1. Epub 2013 Mar 31.
6
Comparison of the value of PCNA and Ki-67 as markers of cell proliferation in ameloblastic tumors.PCNA 和 Ki-67 作为牙源性肿瘤细胞增殖标记物的价值比较。
Med Oral Patol Oral Cir Bucal. 2013 Mar 1;18(2):e174-9. doi: 10.4317/medoral.18573.
7
Cancer testes antigens in breast cancer: biological role, regulation, and therapeutic applicability.癌症睾丸抗原在乳腺癌中的作用：生物学作用、调控及治疗应用。
Int Rev Immunol. 2012 Oct;31(5):302-20. doi: 10.3109/08830185.2012.723511.
8
Cancer/testis antigens and urological malignancies.癌症/睾丸抗原与泌尿系统恶性肿瘤。
Nat Rev Urol. 2012 Jun 19;9(7):386-96. doi: 10.1038/nrurol.2012.117.
9
Cancer/testis (CT) antigens, carcinogenesis and spermatogenesis.癌胚/睾丸（CT）抗原、致癌作用与精子发生
Spermatogenesis. 2011 Jul-Sep;1(3):209-220. doi: 10.4161/spmg.1.3.17990. Epub 2011 Jul 1.
10
Cancer/Testis Antigens as potential predictors of biochemical recurrence of prostate cancer following radical prostatectomy.癌症/睾丸抗原作为前列腺癌根治术后生化复发的潜在预测指标。
J Transl Med. 2011 Sep 14;9:153. doi: 10.1186/1479-5876-9-153.